High Altitude Physiology

Related Subjects: |High Altitude Physiology |Diving Physiology |Trauma Physiology |Exercise Physiology |Gastric Physiology |Rectal Physiology

🏔️ High altitude physiology studies how the human body adapts to chronic hypoxia at elevations >2,500 m (8,200 ft), where atmospheric pressure falls and inspired PO₂ drops. Rapid ascent causes acute mountain sickness (AMS) in 15–80% of people; severe forms (HAPE/HACE) can be fatal without descent. Understanding acclimatisation mechanisms is vital for mountaineers, pilgrims, military personnel, and high-altitude residents.

🌬️ Physiological Responses to High Altitude

• Hypoxia – The Primary Stressor ⚡
  • At sea level: PB = 760 mmHg, PIO₂ ≈ 159 mmHg, PaO₂ ≈ 95–100 mmHg, SaO₂ ≈ 97–99%.
  • At 3,000 m: PB ≈ 523 mmHg, PIO₂ ≈ 110 mmHg, PaO₂ ≈ 60–70 mmHg, SaO₂ ≈ 90–93%.
  • At 5,500 m (Everest Base Camp): PB ≈ 380 mmHg, PIO₂ ≈ 80 mmHg, PaO₂ ≈ 45–50 mmHg, SaO₂ ≈ 80–85%.
  • At 8,848 m (Everest summit): PB ≈ 253 mmHg, PIO₂ ≈ 43 mmHg, PaO₂ ≈ 25–30 mmHg, SaO₂ ≈ 60–70% (life-threatening without O₂).
• Immediate Respiratory Responses 🫁
  • Hypoxic ventilatory response (HVR): ↑ minute ventilation (hyperventilation) within minutes → ↓ PaCO₂ (e.g., 30–35 mmHg at 3,000 m).
  • Respiratory alkalosis (pH ↑ 7.45–7.50 initially) → renal compensation (HCO₃⁻ excretion) over 24–72 h → pH returns toward normal.
  • Longer-term: ↑ lung diffusion capacity, ↑ alveolar ventilation efficiency.
• Cardiovascular Responses ❤️
  • Acute: ↑ heart rate (10–30%), ↑ cardiac output (20–50%) to maintain O₂ delivery.
  • Hypoxic pulmonary vasoconstriction (HPV): ↑ pulmonary artery pressure (mPAP 20–30 mmHg at 3,000 m, >40 mmHg risk HAPE).
  • Chronic: Right ventricular hypertrophy, systemic vasodilation (NO-mediated), ↓ systemic BP.
• Hematological & Oxygen Transport Changes 🩸
  • Acute: Plasma volume ↓ (diuresis) → relative ↑ Hb concentration.
  • Chronic: Erythropoietin (EPO) ↑ within hours → RBC mass ↑ 20–50% over weeks–months (Hb ↑ 1–3 g/dL at 4,000 m).
  • Improved O₂ unloading (right-shifted O₂-Hb curve via ↑ 2,3-DPG).
• Other Adaptations 🔬
  • Mitochondrial efficiency ↑ (more efficient ATP production at low PO₂).
  • Capillary density ↑ in muscle (angiogenesis via HIF-1α/VEGF).
  • Genetic adaptations (e.g., EPAS1/HIF pathway variants in Tibetans/Andeans → blunted polycythaemia, lower Hb at altitude).

⏳ Acclimatisation Timeline

🚨 Altitude-Related Illnesses (Lake Louise Criteria 2018, still standard 2026)

• Acute Mountain Sickness (AMS) 🤕
  • Prevalence: 15–25% at 2,500–3,000 m; 50–80% at >4,000 m.
  • Lake Louise Score ≥3 (headache + ≥1 of: GI, fatigue, dizziness, sleep disturbance).
  • Risk factors: rapid ascent (>500 m/day above 3,000 m), previous AMS, female sex, obesity.
• High-Altitude Pulmonary Edema (HAPE) 🫁💧
  • Prevalence: 0.2–6% above 3,000 m; higher in rapid ascents.
  • Symptoms: dyspnoea at rest, cough (frothy pink sputum), tachycardia, cyanosis, crackles.
  • mPAP >35–45 mmHg → capillary leak; non-cardiogenic pulmonary oedema.
• High-Altitude Cerebral Edema (HACE) 🧠💧
  • Rare (0.1–2% above 4,000 m); often follows AMS.
  • Symptoms: severe headache, ataxia, confusion, hallucinations, coma.
  • Vasogenic oedema from blood-brain barrier disruption (HIF-1α mediated).

🛡️ Prevention & Management (Wilderness Medical Society & UIAA Guidelines 2025–2026)

• Golden rules: Ascend slowly (<500 m/day above 3,000 m), "climb high, sleep low", rest days every 3–4 days.
• Medications:
  • Acetazolamide (Diamox): 125–250 mg BD prophylaxis (starts day before ascent; speeds acclimatisation via metabolic acidosis → ↑ ventilation).
  • Ibuprofen: 600 mg TDS (AMS prevention, non-inferior to acetazolamide in some studies).
  • Dexamethasone: 4 mg q6h (HACE treatment/prevention; not prophylaxis).
  • Nifedipine: 30 mg SR BD (HAPE prophylaxis/treatment; ↓ pulmonary pressure).
  • Sildenafil/Tadalafil: PDE5 inhibitors (off-label HAPE prevention).
• Other: Hydration (3–5 L/day), carbohydrate-rich diet (↑ RQ), avoid alcohol/sedatives, supplemental O₂ or portable hyperbaric chambers (Gamow bag) for severe cases.

Teaching Point 🩺 Hypoxia at altitude → immediate hyperventilation → respiratory alkalosis → renal compensation. Acclimatisation: ↑ ventilation, ↑ EPO → polycythaemia, ↑ tissue O₂ delivery. AMS (headache + symptoms) → descend if moderate/severe. HAPE/HACE = medical emergencies → immediate descent + O₂/dexamethasone/nifedipine. Prevention: slow ascent ("climb high, sleep low"), acetazolamide prophylaxis, avoid rapid gains >500 m/day above 3,000 m.

🔬 Research & Future Directions (2026)

• Genetic factors: EPAS1/HIF2α variants in Tibetans/Andeans → blunted polycythaemia, better tolerance.
• Wearable tech: Continuous SpO₂ + HR monitoring predicts AMS risk (machine learning models 2025–2026).
• Pharmacology: HIF stabilisers/PHD inhibitors (e.g., roxadustat) for pre-acclimatisation or HAPE prevention trials.
• Climate change: Rising treeline → new high-altitude populations; increased lightning/UV risks.

📚 References (Feb 2026)

• Wilderness Medical Society Guidelines: Altitude Illness (2025 update).
• Luks AM et al. High-Altitude Medicine. NEJM 2024 review (still key).
• West JB. High Life (3rd ed., 2025).
• Recent: Genetic adaptations (Nature Genetics 2025), portable oximetry prediction models (High Alt Med Biol 2026).